Analysis of Free Circulating Messenger Ribonucleic Acids in Serum Samples from Late-Onset Spinal Muscular Atrophy...

Area of Science:

• Genetics and Molecular Biology
• Neurology
• Biomarker Discovery

Background:

• Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder characterized by progressive muscle weakness and atrophy due to motor neuron degeneration.
• Current SMN-enhancing therapies are effective but do not benefit all patients, particularly adults with late-onset SMA or advanced disease.
• There is a need for novel therapeutic targets and prognostic biomarkers to improve treatment outcomes in SMA.

Purpose of the Study:

• To identify novel molecular targets for SMA treatment beyond SMN enhancement.
• To discover potential biomarkers that predict treatment response in SMA patients.
• To investigate serum gene expression alterations in late-onset SMA patients undergoing nusinersen therapy.

Main Methods:

• Serum samples from late-onset SMA types 2 and 3 patients were analyzed using high-throughput nCounter NanoString technology.
• Gene expression profiles were assessed before and six months after nusinersen treatment.
• Differential gene expression was correlated with SMA subtype and clinical outcome scales.

Main Results:

• Four genes (AMIGO1, CA2, CCL5, TLR2) showed significantly altered transcript counts in SMA patients' serum compared to healthy controls.
• Expression patterns varied based on SMA subtype and treatment response.
• No significant changes in these gene expressions were observed six months post-nusinersen treatment compared to baseline.

Conclusions:

• The identified genes (AMIGO1, CA2, CCL5, TLR2) represent potential SMN-independent therapeutic targets for SMA.
• These genes may serve as biomarkers for treatment response in SMA patients.
• Further research into these targets could complement existing SMN-enhancing therapies for broader patient benefit.